S5 Ep36: FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer
Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.
16m
•
Aug 26, 2021